As expected, Gefitinib, an inhibitor of EGFR approved for the clinical treatment of cancers [37], induced a dose-dependent reduction of the cell viability in MDA-MB-231 cells, and this is attenuated by the enforced expression of PELI1 (Fig. S3C). Here, EGFR is linked to cancer.